| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED DECEMBER 2017. Refer to TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | ibrutinib (Imbruvica®) | |
| Formulation | 140 mg hard capsule | |
| Reference number | 2199 | |
| Indication | Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) |
|
| Company | Janssen-Cilag Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 10/06/2016 | |
| Date of issue | 15/06/2016 | |
| NICE guidance | TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
|